Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Gisslinger · SciRah

Researcher profile · Semantic Scholar

H. Gisslinger

Share profile

H. Gisslinger — researcher profile on SciRah

h-index: 75
Works: 393
Citations: 27K

Most-cited papers

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
T. Barbui, J. Thiele, H. Gisslinger, H. Kvasnicka +4 more
2018Blood Cancer Journal580 citations Open access
Semantic Scholar
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk +57 more
2020The Lancet Haematology327 citations Open access
Semantic Scholar
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
P. Richardson, A. Oriol, M. Beksaç, A. Liberati +161 more
2019The Lancet Oncology323 citations Open access
Semantic Scholar
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
B. Snijder, G. Vladimer, N. Krall, K. Miura +30 more
2017The Lancet Haematology156 citations Open access
Semantic Scholar
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
G. Greiner, Bettina Sprinzl, A. Górska, F. Ratzinger +17 more
2020Blood149 citations Open access
Semantic Scholar
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
E. Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, B. Gisslinger +33 more
2018Blood143 citations Open access
Semantic Scholar
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
M. Marchetti, A. Vannucchi, M. Griesshammer, C. Harrison +12 more
2022The Lancet Haematology113 citations
Semantic Scholar
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk +13 more
2022Leukemia109 citations Open access
Semantic Scholar
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk +13 more
2023Leukemia80 citations Open access
Semantic Scholar
Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
C. Harrison, A. Vannucchi, J. Kiladjian, H. Al-Ali +9 more
2017Leukemia77 citations Open access
Semantic Scholar
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
B. Kubešová, Š. Pavlová, J. Malčíková, J. Kabáthová +16 more
2017Leukemia74 citations Open access
Semantic Scholar
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio, P. Guglielmelli, L. Pieri, M. Primignani +31 more
2019American journal of hematology/oncology72 citations Open access
Semantic Scholar
The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera
T. Barbui, A. Vannucchi, A. Carobbio, E. Rumi +11 more
2017American journal of hematology/oncology68 citations Open access
Semantic Scholar
Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms.
Fiorella Schischlik, R. Jäger, F. Rosebrock, E. Hug +20 more
2019Blood63 citations Open access
Semantic Scholar
Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
G. Jeryczynski, J. Thiele, B. Gisslinger, A. Wölfler +14 more
2017American journal of hematology/oncology59 citations Open access
Semantic Scholar
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
F. Cervantes, D. Ross, A. Radinoff, F. Palandri +13 more
2021Leukemia55 citations Open access
Semantic Scholar
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
E. Verger, J. Soret-Dulphy, N. Maslah, L. Roy +10 more
2018Blood Cancer Journal55 citations Open access
Semantic Scholar
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
A. Vannucchi, P. T. Te Boekhorst, C. Harrison, G. He +8 more
2018Haematologica44 citations Open access
Semantic Scholar
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
M. Anker, M. Frey, G. Goliasch, P. Bartko +8 more
2020European Journal of Heart Failure39 citations Open access
Semantic Scholar
Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study
M. Antlanger, Tobias Dust, T. Reiter, Alexandra Böhm +14 more
2018BMC Cancer36 citations Open access
Semantic Scholar
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
C. Pecquet, Nicolas Papadopoulos, Thomas Balligand, I. Chachoua +38 more
2022Blood34 citations Open access
Semantic Scholar
Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy
C. Pecquet, Thomas Balligand, I. Chachoua, Anita Roy +26 more
2018Blood34 citations
Semantic Scholar
Diagnostic impact of the 2016 revised who criteria for polycythemia vera
T. Barbui, J. Thiele, H. Gisslinger, A. Carobbio +2 more
2017American journal of hematology/oncology34 citations Open access
Semantic Scholar
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
A. Tefferi, G. Barosi, Francesco Passamonti, J. Hernández-Boluda +34 more
2024Blood32 citations Open access
Semantic Scholar
Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer
H. Arfsten, A. Cho, S. Prausmüller, G. Spinka +12 more
2021Frontiers in Cardiovascular Medicine28 citations Open access
Semantic Scholar
Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
S. Durrant, A. Nagler, P. Guglielmelli, D. Lavie +8 more
2019Haematologica28 citations Open access
Semantic Scholar
Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk +13 more
2025HemaSphere26 citations Open access
Semantic Scholar
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis
F. Barraco, R. Greil, R. Herbrecht, B. Schmidt +9 more
2020British Journal of Haematology25 citations Open access
Semantic Scholar
Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk +14 more
2018Blood24 citations Open access
Semantic Scholar
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
T. Barbui, A. Carobbio, Juergen Thiele, N. Gangat +21 more
2023Blood Cancer Journal23 citations Open access
Semantic Scholar
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
J. D. Milosevic Feenstra, R. Jäger, Fiorella Schischlik, Daniel Ivanov +13 more
2022American journal of hematology/oncology19 citations Open access
Semantic Scholar
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients
N. Pavo, H. Arfsten, A. Cho, G. Goliasch +9 more
2019Scientific Reports19 citations Open access
Semantic Scholar
Impact of white blood cell counts at diagnosis and during follow‐up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis
V. Buxhofer-Ausch, B. Gisslinger, M. Schalling, A. Gleiss +5 more
2017British Journal of Haematology19 citations Open access
Semantic Scholar
Germline Genetic Factors Influence Outcome of Interferon Alpha Therapy in Polycythemia Vera.
R. Jäger, H. Gisslinger, Elisabeth Fuchs, E. Bogner +9 more
2020Blood18 citations Open access
Semantic Scholar
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients
N. Pavo, M. Raderer, G. Goliasch, R. Wurm +19 more
2017OncoTarget18 citations Open access
Semantic Scholar
GDF‐15 in solid vs non‐solid treatment‐naïve malignancies
H. Arfsten, A. Cho, C. Freitag, M. Raderer +10 more
2019European Journal of Clinical Investigation17 citations Open access
Semantic Scholar
Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia
V. Buxhofer-Ausch, M. Steurer, S. Sormann, E. Schloegl +8 more
2018European Journal of Haematology17 citations Open access
Semantic Scholar
Pre-PMF emerging as important subgroup of MPN.
H. Gisslinger
2017Blood17 citations
Semantic Scholar
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
A. Carobbio, A. Vannucchi, E. Rumi, V. De Stefano +9 more
2023Blood Cancer Journal16 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results
H. Gisslinger, V. Buxhofer-Ausch, J. Thaler, E. Forjan +16 more
2018Blood16 citations
Semantic Scholar
The WHO diagnostic criteria for polycythemia vera—role of red cell mass versus hemoglobin/hematocrit level and morphology
L. Jaković, M. Gotic, H. Gisslinger, I. Soldatovic +9 more
2018Annals of Hematology15 citations
Semantic Scholar
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
M. Schalling, A. Gleiss, B. Gisslinger, A. Wölfler +7 more
2017Blood Cancer Journal15 citations Open access
Semantic Scholar
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
T. Barbui, A. Ghirardi, V. Empson, Francesca Fenili +12 more
2025Blood Cancer Journal14 citations Open access
Semantic Scholar
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia
V. Buxhofer-Ausch, D. Wolf, S. Sormann, E. Forjan +7 more
2020European Journal of Haematology14 citations Open access
Semantic Scholar
Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk +14 more
201714 citations
Semantic Scholar
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Dorothea Hose, M. Schreder, Jochen Hefner, M. Bittrich +8 more
2020Journal of Cancer Research and Clinical Oncology13 citations Open access
Semantic Scholar
Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count
T. Gremmel, B. Gisslinger, H. Gisslinger, S. Panzer
2018Translational Research: The Journal of Laboratory and Clinical Medicine13 citations
Semantic Scholar
Recommendations for the diagnosis and treatment of patients with polycythaemia vera
A. Hatalova, J. Schwarz, M. Gotic, M. Penka +15 more
2018European Journal of Haematology13 citations
Semantic Scholar
Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk +13 more
202012 citations
Semantic Scholar
Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms
Daniel Ivanov, J. D. Milosevic Feenstra, I. Sadovnik, H. Herrmann +21 more
2023American journal of hematology/oncology11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Gisslinger×20
Invite
B. Gisslinger — researcher profile on SciRah
R. Kralovics×19
Invite
R. Kralovics — researcher profile on SciRah
J. Kiladjian×12
Invite
J. Kiladjian — researcher profile on SciRah
A. Vannucchi×11
Invite
A. Vannucchi — researcher profile on SciRah

×11

Invite

M. Krauth — researcher profile on SciRah

M. Schalling×10

Invite

M. Schalling — researcher profile on SciRah

Invite

C. Klade — researcher profile on SciRah

Invite

J. Thiele — researcher profile on SciRah

Invite

M. Egyed — researcher profile on SciRah

Invite

E. Rumi — researcher profile on SciRah

Invite

T. Barbui — researcher profile on SciRah

Invite

P. Georgiev — researcher profile on SciRah